Overview from articles ...8 Dec 2017 15:08
Though numerous women become pregnant without difficulty, many others plan their pregnancies, often using urine-based tests that are designed to tell them when they are at their most fertile. These work for the average woman but, for a sizeable minority, they do not.
Research has shown that 30 per cent of women with unexplained infertility issues have low levels of the luteinising hormone associated with ovulation.
This does not mean they cannot have children. But it does mean off-the-shelf fertility testing kits do not work for them.
Concepta has developed the first kit – MyLotus – to tell women exactly what their luteinising hormone levels are, even if they are lower (or higher) than the norm. Women simply perform a urine test at home and place the swab in a hand-held meter, which provides instant and highly accurate readings.
Not only does the meter provide detailed, personalised information, but Concepta has also developed easier-to-use urine sampling equipment to make the whole process as simple as possible.
The procedure can be repeated over days or months, telling women when they are most likely to become pregnant. There is also an app, that allows users to create a diary of their hormonal cycle, useful both for women and their doctors, if they ultimately resort to medical intervention.
The meter even tells women if they have already become pregnant, again with ease and reliability.
Concepta’s testing kit and app have been approved in China and the firm is expected to begin selling its products there this year.
Meanwhile, plans for Europe are well advanced. The company, which is based in Sharnbrook, Bedfordshire, is developing a manufacturing site in Yorkshire to produce the meters and testing kits in volume.
The meters are expected to go on sale for between £250 and £300 and Concepta believes that demand should run into several million, growing steadily as the brand becomes more established.
The group is also working on related concepts, such as stress kits, which both men and women could use to measure their stress levels. People trying for a baby often experience high levels of stress, which can affect ovulation in women and sperm quality in men.
Easy-to-use kits could show couples when and if stress is affecting fertility, allowing them to seek treatment at an early stage. Such kits could also find a market outside of fertility treatment, given the increasing prevalence of stress-related disease.
Henau and his senior colleagues have decades of experience in the fertility industry, having worked on the market-leading ovulation and pregnancy testing kit, Clearblue, now owned by Procter & Gamble.
Worth noting that AVA (US based) have developed a bracelet that tries to give a similar advanced view - this is retailing now for £199. Its available mail order only in EU from America. So if CPT can gain success in China (no competition) then enter EU they will be the on
Sign In
Follow the stocks
